Tuesday, October 12, 2010 - 09:31 in Health & Medicine
Women with an aggressive subtype of metastatic breast cancer appear to live an average of almost five months longer when treated with iniparib plus chemotherapy, compared to chemotherapy alone, the results of a randomized Phase-II trial show.
- Iniparib extends overall survival in metastatic triple-negative breast cancerTue, 12 Oct 2010, 10:36:18 EDT
- Prolonging first-line chemotherapy improves outcomes for patients with metastatic breast cancerTue, 12 Oct 2010, 10:36:13 EDT
- Clinical trial shows benefit to adding avastin to neoadjuvant chemotherapy in breast cancer patientsTue, 23 Aug 2011, 14:35:55 EDT
- Abiraterone acetate improves survival in metastatic castration-resistant prostate cancerTue, 12 Oct 2010, 11:07:26 EDT
- Considering combination versus sequential chemotherapy in metastatic breast cancerWed, 5 Aug 2009, 22:43:14 EDT